Revreboot - October CHMP Meeting (EMEA/H/D/002831), ((substance to be reviewed) insulin-like growth factor-i (igf-i) segment), (hard-to-heal wounds, primarily venous leg ulcers) List of Questions adopted on 23.01.2014. List of Outstanding Issues adopted on 25.09.2014. • Request from the applicant for an additional extension of clock stop to respond to the List of Outstanding Issues adopted in September 2014: For adoption
The applicant for the extension of the clock stop was TIS (or was it BSI or maybe the EMA itself?)
This thread is BS.
Big Pharma does't even know (and couldn't care less) who TIS and what it does.
Accusing the EMA does show how delusional some of these accusers are.
TIS Price at posting:
31.0¢ Sentiment: Hold Disclosure: Held